Market Cap | 295.17M | P/E | - | EPS this Y | 11.40% | Ern Qtrly Grth | - |
Income | - | Forward P/E | 23.00 | EPS next Y | 12.90% | 50D Avg Chg | 9.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -4.00% |
Dividend | N/A | Price/Book | 30.26 | EPS next 5Y | - | 52W High Chg | -46.00% |
Recommedations | 1.80 | Quick Ratio | - | Shares Outstanding | 226.14M | 52W Low Chg | 68.00% |
Insider Own | 45.78% | ROA | - | Shares Float | - | Beta | - |
Inst Own | 9.50% | ROE | - | Shares Shorted/Prior | 15.96M/16.40M | Price | 1.15 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 488,290 | Target Price | 7.20 |
Oper. Margin | - | Earnings Date | Feb 13 | Volume | 213,572 | Change | -1.71% |
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
BTIG | Buy | Oct 31, 22 |
Chardan Capital | Buy | Sep 13, 22 |
HC Wainwright & Co. | Buy | Aug 27, 20 |
Oppenheimer | Outperform | Aug 18, 20 |
HC Wainwright & Co. | Buy | May 27, 20 |
Ladenburg Thalmann | Buy | Sep 11, 19 |
H.C. Wainwright | Buy | Jul 18, 19 |
Oppenheimer | Outperform | May 16, 19 |
Ascendiant Capital | Buy | Nov 25, 20 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Evanson Jeff | Chief Commercial Off.. Chief Commercial Officer | Jan 20 | Sell | 1.11 | 267,000 | 296,370 | 745,975 | 01/24/23 |
Evanson Jeff | Chief Commercial Off.. Chief Commercial Officer | Jan 17 | Sell | 1.26 | 164,155 | 206,835 | 1,012,975 | 01/19/23 |
HILZINGER KURT J | Director Director | Oct 04 | Buy | 1.26 | 111,203 | 140,116 | 473,117 | 10/05/22 |
Dagnon Terry | Chief Operating Offi.. Chief Operating Officer | Jun 21 | Buy | 1.05 | 10,000 | 10,500 | 1,173,058 | 06/23/22 |
TRENARY C RUSSELL III | CEO and President CEO and President | Jun 21 | Buy | 1.06 | 19,925 | 21,120 | 54,925 | 06/23/22 |
HILZINGER KURT J | Director Director | Mar 01 | Buy | 1.69 | 27,708 | 46,827 | 273,117 | 03/03/22 |
HILZINGER KURT J | Director Director | Feb 24 | Buy | 1.53 | 47,160 | 72,155 | 245,409 | 02/28/22 |
HILZINGER KURT J | Director Director | Feb 22 | Buy | 1.47 | 175,132 | 257,444 | 198,249 | 02/23/22 |